If you or your child just got an ADHD diagnosis, the treatment landscape looks confusing from the outside. There are dozens of brand names, most of them variations of the same two drugs. The medicines that work best are controlled substances, and many patients spent parts of 2023 and 2024 calling pharmacy after pharmacy because of a national shortage. About 7 in 10 adults taking stimulant medication had trouble filling a prescription that year. And if you are an adult, especially a woman, there is a good chance nobody even thought to test you for ADHD until recently. More than half of US adults with the diagnosis only got it in adulthood.
So here is the full picture: what is approved today, what researchers are testing right now, and why new ADHD drugs take so long to arrive.
Looking for treatment options for ADHD?
Browse open ADHD clinical trials near you! We'll handle the follow-up.
What is approved today
Stimulants. Almost every stimulant prescribed for ADHD comes from one of two families: methylphenidate (Ritalin, Concerta, Focalin, and others) or amphetamine (Adderall, Vyvanse, and others). Together, they show up as around 30 different brand names. The differences between brands are mostly about how fast the medicine kicks in and how long it lasts, not what it actually does. All of them work by raising dopamine and norepinephrine, two brain chemicals tied to attention and impulse control. Stimulants have been studied for decades and work well for most people. Their main downsides are side effects for some people and strict rules around prescribing them.
Nonstimulants. For people who don't tolerate stimulants, don't respond to them, or just can't deal with the refill hassle, there are four approved options. Atomoxetine works on norepinephrine. Viloxazine (Qelbree, approved in 2021) also targets norepinephrine, but through a different path. Extended-release guanfacine and extended-release clonidine calm down overactive signaling in the brain, and both are often used in children.
The newest one. In July 2026, the FDA approved centanafadine, sold as Simtriyo (Otsuka), for adults and for children 6 and older who weigh at least 20 kg. It's the first ADHD medicine that works on three brain chemicals at once: norepinephrine, dopamine, and serotonin. In its studies, both children and adults improved significantly more on the drug than on placebo after six weeks. It's a genuinely new approach in a field that hadn't seen one in years.
To be clear, none of this is treatment advice. Which medicine fits you depends on your history, your other health conditions, and what your doctor thinks is best.
What researchers are studying now
The field is busier than most people assume. As of August 2026, 183 ADHD studies were recruiting worldwide, and new drugs are only part of the picture.
Solriamfetol (Axsome). This drug is already approved for excessive sleepiness in narcolepsy and sleep apnea, and now Axsome is testing it for ADHD too. In a Phase 3 study called FOCUS, with just over 500 adults, people taking solriamfetol improved about 18 points on a standard symptom scale after six weeks, compared to about 14 points on placebo. Just over half of treated patients responded, versus about 4 in 10 on placebo. Axsome is now testing it in younger age groups too. Two Phase 3 studies of 468 people each are recruiting right now, one in adolescents with ADHD and one in children with ADHD, and both are listed on our ADHD trials page.
Centanafadine follow-up work. Before it got approved, Otsuka also ran a positive study of centanafadine in adults who have both ADHD and anxiety. That matters because in real life, people often have both conditions, but trials rarely include them.
The academic layer. Drug studies aren't the whole story. Most ADHD studies recruiting right now come from universities and hospitals, places like NIMH, Massachusetts General Hospital, UCLA, King's College London, and Karolinska Institutet. They're testing things like behavioral treatments, working memory training, virtual reality tools, and non-drug supplements. Rutgers, for example, is running a virtual reality study for ADHD with about 250 participants. These sponsors also study the people drug trials usually skip.
Why new ADHD treatments take time
The placebo problem. In Axsome's adult study, the placebo group improved by about 14 points. Not the drug group, the placebo group. People in ADHD trials get more structure, attention, and regular checkins, and symptoms are measured with rating scales, so just paying closer attention can move the numbers. When placebo does this well, a real drug has to clear a much higher bar to prove it's actually working.
The comparator problem. Stimulants already work well for most people. So a new drug rarely wins by working better, it has to win some other way: fewer side effects, no risk of misuse, or helping people the older drugs don't serve well, like those with both ADHD and anxiety.
The Schedule II problem. Stimulants are controlled substances with strict rules around storage, prescribing, and supply. That makes running trials harder, and it makes everyday access harder too, which is exactly what caused the 2023-2024 shortage. By 2024, about half of US adults with ADHD had used telehealth for their care at some point, just to work around it. This is a big part of why so much research now goes into nonstimulants like Qelbree and Simtriyo.
The representation problem. ADHD research spent decades focused mostly on school-age boys. Adults, and especially women, were barely studied, which is one reason more than half of adults with ADHD weren't diagnosed until adulthood. Many current trials now deliberately recruit adults, and some are studying situations nobody looked at before. The University of Pittsburgh, for example, is enrolling 80 people in a study of expectant mothers managing ADHD. That gap is slowly closing.
Why ADHD symptoms in women get missed
The gap around women isn't random. Girls and women have inattentive symptoms just as often as boys and men do. What they're less likely to have are the loud, hyperactive symptoms, the ones parents and teachers usually notice first. Quiet trouble with focus, staying organized, or finishing things is easy to miss at school. Many girls also learn to hide their struggles to fit in, something specialists call masking. So some get told they have anxiety or depression first, and only later does anyone consider ADHD. The numbers show it: in childhood, about two boys get diagnosed for every girl, but by adulthood, men and women are diagnosed at roughly the same rate. All those years of missed answers are exactly why adult ADHD studies now recruit women on purpose.
Does ADHD affect more than attention?
Yes, and it's worth knowing even if it's a little uncomfortable. Nearly 8 in 10 children with ADHD have at least one other condition. About half have behavior problems, and roughly 4 in 10 have anxiety. And about 3 in 10 children with ADHD currently get no medication or behavioral treatment at all.
There's also research looking at the bigger picture over a lifetime. A 2025 UK study compared about 30,000 adults with diagnosed ADHD to about 300,000 similar adults without it. Life expectancy was 4.5 to 9 years shorter for men and 6.5 to 11 years shorter for women with ADHD. Before that number worries you, here's what the researchers actually concluded: most of that gap comes from things that can be treated or changed, like smoking and unmet health needs, not from ADHD itself. That's an average across tens of thousands of people, it doesn't predict what happens to any one person. What it does say is that ADHD deserves real, ongoing medical attention, not just a prescription refilled once a year. If any of this worries you, talk to your doctor.
Common myths about ADHD
"ADD is a different condition."
It is the same condition under its old name. ADD became an official diagnosis in 1980, in two forms: with hyperactivity and without. A 1987 revision of the diagnostic manual folded both into ADHD, and the current manual, the DSM-5-TR, does not include ADD at all. If your old paperwork says ADD without hyperactivity, today that corresponds to predominantly inattentive ADHD.
"ADHD is a childhood thing you grow out of."
About 15.5 million US adults have a current ADHD diagnosis. For many people symptoms continue well into adulthood, and plenty of adults are diagnosed for the first time in their 30s, 40s, or later.
"ADHD is a form of autism."
No. They are separate neurodevelopmental diagnoses. One person can have both, and some trials now study that overlap directly, but having ADHD does not put you on the autism spectrum.
The three presentations of ADHD and what care usually looks like
ADHD has no stages. Instead, the signs of ADHD sort into three presentations, based on which symptoms are strongest at the time of diagnosis. Whatever the presentation, the diagnosis always requires that some symptoms showed up before age 12. And the label is not permanent: the CDC notes that because symptoms can change over time, the presentation can change as well.
Predominantly inattentive ADHD
Trouble focusing dominates. A person with this presentation finds it hard to organize tasks, finish what they start, hold on to details, or follow long instructions and conversations. Distractions pull them away easily, and pieces of daily routines get forgotten. It is the easiest presentation to miss, since there is no disruptive behavior to catch a teacher's eye, and that is a big part of why so many girls and women get their answer late. Care typically involves medication, behavioral strategies, or both, plus school or workplace accommodations.
Predominantly hyperactive impulsive ADHD
Restlessness leads. Fidgeting, talking a lot, trouble sitting still or waiting for a turn, interrupting people, grabbing things, acting without thinking it through. It is the most visible presentation and often the earliest diagnosed. Typical care again combines medication and behavioral treatment. And for children younger than 6, the American Academy of Pediatrics recommends parent training in behavior management as the first treatment, before any medication.
Combined ADHD
Both symptom groups show up at similar strength. Care follows the same pattern, tailored to whichever symptoms cause the most trouble day to day.
These are descriptions of usual practice, not recommendations. Your clinician decides what fits your case.
How to find an ADHD study
If you want to be part of this research, the path is simpler than most people expect. Browse the recruiting ADHD trials on AllClinicalTrials.com and pick studies that match your age and situation, whether that's a working memory training study for adolescents or a binaural beats study testing a non-drug, sound-based approach in adults, and apply. The application takes about 5 minutes, and the study team contacts you to check eligibility and answer questions. You commit to nothing until you have gone through informed consent.
Common questions
What is ADHD, in simple terms? ADHD, short for attention deficit hyperactivity disorder, is a brain based condition that makes it hard to regulate focus, restrain impulses, and organize everyday tasks. It always begins in childhood, with some symptoms present before age 12, though plenty of people only get the diagnosis as adults. Doctors describe it in three presentations, depending on which symptoms are strongest.
What are the types of ADHD? ADHD comes in three presentations, not stages or separate diseases: predominantly inattentive, predominantly hyperactive-impulsive, and combined. Inattentive means trouble focusing, organizing, and finishing things stands out most. Hyperactive-impulsive means restlessness, fidgeting, and acting without thinking dominate. Combined means both are present at similar levels. And the picture is not fixed: symptoms can change over time, so a person's presentation can change too.
Is ADHD genetic? Genes matter a lot. Across dozens of twin studies, genetics explained about 74 percent of ADHD risk. And ADHD runs in families: a parent, brother, sister, or child of someone with ADHD has about nine times the average risk of having it too.
What causes ADHD? Doctors do not know the exact cause of ADHD. Genes play an important role in a person's risk. Scientists have also identified other possible risk factors, like lead exposure during pregnancy or at a young age, alcohol and tobacco use during pregnancy, and head injuries in childhood. Researchers are still working out how these pieces fit together.
Is ADHD a disability? It can be. Under US law ADHD can count as a disability when symptoms substantially limit major life activities, which is why schools and employers can offer accommodations. Whether that applies depends on how ADHD affects the individual person.
Is ADHD on the autism spectrum? No. ADHD and autism are separate diagnoses. Both are neurodevelopmental, and one person can have both. Some studies recruiting now look at people who have ADHD and autism together.
See ADHD clinical trials recruiting now.
New studies for children, adolescents, and adults are enrolling across the US. Browse ADHD clinical trials and apply in about 5 minutes.